Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Change in Account Payables (2022 - 2025)

Coeptis Therapeutics Holdings has reported Change in Account Payables over the past 4 years, most recently at $101115.0 for Q4 2025.

  • Quarterly results put Change in Account Payables at $101115.0 for Q4 2025, down 25.39% from a year ago — trailing twelve months through Dec 2025 was -$381012.0 (down 154.12% YoY), and the annual figure for FY2025 was -$381012.0, down 154.12%.
  • Change in Account Payables for Q4 2025 was $101115.0 at Coeptis Therapeutics Holdings, up from -$241188.0 in the prior quarter.
  • Over the last five years, Change in Account Payables for COEPW hit a ceiling of $937694.0 in Q4 2023 and a floor of -$241188.0 in Q3 2025.
  • Median Change in Account Payables over the past 4 years was $41539.5 (2022), compared with a mean of $47166.2.
  • Biggest five-year swings in Change in Account Payables: surged 545.43% in 2023 and later plummeted 269.3% in 2024.
  • Coeptis Therapeutics Holdings' Change in Account Payables stood at -$228851.0 in 2022, then surged by 509.74% to $937694.0 in 2023, then plummeted by 85.55% to $135521.0 in 2024, then fell by 25.39% to $101115.0 in 2025.
  • The last three reported values for Change in Account Payables were $101115.0 (Q4 2025), -$241188.0 (Q3 2025), and -$91832.0 (Q2 2025) per Business Quant data.